stockrow
Monday 9 November 2026
Export EVMN’s income statement to Excel — free account
Evommune Inc.
EVMNEvommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024.
- EPS
- +89.9%
- Free cash flow
- +21.8%
Quarter to June 2026, against a year earlier
6.65
0.28
+4.40%
Follow EVMN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 7 | 13 | — | +85.7% | — | 0 | 0 | (68.7%) | |
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | 100.00 | — | 0.0 pt | ||||||
| EBT | — | — | — | — | — | — | — | — | (67) | (69) | (95) | +3.1% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | (954.40) | (529.77) | 0.00 | +424.6 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (67) | (69) | (95) | +3.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 4.64 | 2.12 | 0.00 | (54.4%) | |||||
| Earnings | — | — | — | — | — | — | — | — | (45.29) | (11.22) | (11.03) | (75.2%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (38.59) | (12.46) | (2.05) | (67.7%) | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.06) | (0.04) | (0.01) | (34.4%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (38.65) | (12.49) | (2.07) | (67.7%) | ||||||
| Book value | — | — | — | — | — | — | — | — | 31.52 | 33.50 | 7.68 | +6.3% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 2 | 6 | 19 | +307.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.51 | 0.87 | 0.3 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.57 | 0.57 | (0.54) | 0.6 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (58) | (76) | (74) | +31.4% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | (1) | +167.0% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (58) | (77) | (75) | +31.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 46 | 136 | 187 | +194.7% | |||||
| Net debt | — | — | — | — | — | — | — | — | (72) | (149) | (200) | +108.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 48 | 206 | 278 | +332.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (45.76) | (62.71) | (45.8) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (89.61) | (82.46) | (89.6) pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (224.59) | (141.99) | (224.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 45 | 48 | — | +6.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.16 | 0.27 | — | +74.1% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2025 · fundamentals updated 25 Oct 2026
Evommune Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio, Inc. | $280.4M | — (loss-making) | — | — | n/m | −35.72% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $254.8M | — (loss-making) | — (loss-making) | +138.87% (above 0%: growing) | n/m | +20.36% (above 0%: growing) | 100.00% | (738.76%) | Compare |
| LRMR Larimar Therapeutics, Inc. | $248.3M | — (loss-making) | — | — | n/m | −127.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $241.3M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | |
| ABEO Abeona Therapeutics Inc. | $238.5M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | Compare |
| IMRX Immuneering Corporation | $238.3M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −40.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LXEO Lexeo Therapeutics, Inc. | $237.2M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VNDA Vanda Pharmaceuticals Inc. | $231.0M | — (loss-making) | — (loss-making) | +24.10% (above 0%: growing) | n/m | +9.57% (above 0%: growing) | 94.05% | (33.69%) | Compare |
| FATE Fate Therapeutics, Inc. | $223.1M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| Median of peers | $238.4M | — | — | +24.10% | — | +9.27% | 31.65% | (16.84%) |
Pay and ownership Proxy statement filed 21 April 2026
Ownership
Directors and executive officers, together
31.10%
LSP
14.70%
Felice Verduyn-van Weegen
14.70%
Entities Affiliated with RA Capital
9.70%
Entities Affiliated with Pivotal bioVenture
9.40%
Rob Hopfner, R.Ph., Ph.D.
9.40%
BioDiscovery
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement